Secondary Logo

Journal Logo

CORRECTION

Correction to: Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase

Lee, Hye Won MD, PhD; Kim, Eun Hwa PhD; Lee, Jinae PhD; Kim, Seung Up MD, PhD; Park, Jun Yong MD, PhD, Do; Kim, Young MD, PhD; Ahn, Sang Hoon MD, PhD; Han, Kwang-Hyub MD; Kim, Beom Kyung MD, PhD

Clinical and Translational Gastroenterology: May 2020 - Volume 11 - Issue 5 - p e00183
doi: 10.14309/ctg.0000000000000183
  • Free

Correction to:Clinical and Translational Gastroenterology2020;11(3):e00140. https://doi.org/10.14309/ctg.0000000000000140

In the March 2020 issue of Clinical and Translational Gastroenterology, in “Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase” the authors would like to revise the Study Highlights section. The updated Study Highlights appears below.

Study Highlights

WHAT IS KNOWN

  • ✓ Antiviral therapy is not recommended for patients with hepatitis B e antigen-positive chronic hepatitis B virus infection who have persistently elevated but normal alanine aminotransferase (pEDNA group).
  • ✓ There is little consensus regarding early NUC treatment for pEDNA group.

WHAT IS NEW HERE

  • ✓ The cumulative hepatocellular carcinoma risk in the pEDNA group was minimal comparable with that of the inactive carrier group.

TRANSLATIONAL IMPACT

  • ✓ Among untreated pEDNA group, patients with an intermediate serum HBV DNA level are more likely to develop HCC. Further studies are needed.

© 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology